Osaka, Japan

Miki Hashizume



Average Co-Inventor Count = 4.4

ph-index = 2

Forward Citations = 7(Granted Patents)


Company Filing History:


Years Active: 2017-2025

Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: Miki Hashizume: Innovator in Anti-Tumor Agents

Introduction

Miki Hashizume is a prominent inventor based in Osaka, Japan. She has made significant contributions to the field of pharmaceuticals, particularly in the development of anti-tumor agents. With a total of 6 patents, her work focuses on innovative compounds that target cancer cells.

Latest Patents

One of her latest patents involves dihydrochromene derivatives. This invention relates to a compound that serves as a novel anti-tumor agent targeting cancer stem cells (CSCs). These CSCs are believed to play a crucial role in the persistent proliferation of malignant tumors, metastasis, recurrence of cancer, and resistance to anti-tumor agents. Another significant patent is for a 1,4-disubstituted imidazole derivative. This compound exhibits a potent inhibitory effect on the sphere-forming capacity of cancer cells and is useful as an orally-available anti-tumor agent.

Career Highlights

Miki Hashizume has worked with notable companies such as Sumitomo Dainippon Pharma Co., Ltd. and Sumitomo Pharma Co., Ltd. Her experience in these organizations has contributed to her expertise in pharmaceutical innovations.

Collaborations

Throughout her career, Miki has collaborated with esteemed colleagues, including Hitoshi Ban and Manabu Kusagi. These partnerships have further enhanced her research and development efforts in the field of anti-cancer therapies.

Conclusion

Miki Hashizume's innovative work in developing anti-tumor agents showcases her dedication to advancing cancer treatment. Her contributions are vital in the ongoing fight against cancer, and her patents reflect her commitment to improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…